# Novel use of peak optimized particle therapy for the delivery of three-dimensional spatially fractionated radiotherapy

**Authors:** James W. Snider, Pouya Sabouri, Sina Mossahebi, Arpit M. Chhabra, Jason K. Molitoris, Tejan Diwanji, Katja M. Langen, William F. Regine, Mingyao Zhu, Charles B. Simone

PMC · DOI: 10.3389/fonc.2026.1736260 · Frontiers in Oncology · 2026-03-11

## TL;DR

This paper introduces a new proton therapy method for delivering 3D spatially fractionated radiotherapy, aiming to improve treatment precision and reduce damage to healthy tissues.

## Contribution

The novel technique uses a patented proton pencil beam scanning method to deliver 3D spatially fractionated radiotherapy in a LATTICE format.

## Key findings

- The proposed method optimizes radiobiologic effect by prioritizing pristine Bragg peak delivery.
- It minimizes dose to normal tissues and superficial areas compared to traditional methods.
- The technique allows for new applications of SFRT across treatment courses.

## Abstract

Spatially fractionated radiotherapy (SFRT) has been delivered safely and effectively mostly utilizing beamlets of megavoltage photons in recent years. Particle therapy offers the promise of improved dose distributions with less exposure of surrounding normal tissues. However, most efforts have focused on mimicking the beamlets of traditional SFRT two-dimensional therapy (also known as GRID), potentially sacrificing advantages that could be achieved with scanned particle beams. We, herein, lay out the rationale for and execution of a novel pencil beam scanning proton therapy technique for SFRT that prioritizes pristine Bragg peak delivery in an interleaved and rotated three-dimensional SFRT (LATTICE) format. We propose that this patented (US11478665B2) technique optimizes particle SFRT therapy radiobiologic effect, minimizes normal tissue and superficial dose, and allows for alternative SFRT applications across a course of therapy. This technique lends itself to further exploration in delivery techniques, fractionation, and ultra-high dose rates.

## Full-text entities

- **Chemicals:** US11478665B2 (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13013014/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13013014/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC13013014/full.md

---
Source: https://tomesphere.com/paper/PMC13013014